Very late relapse of acute promyelocytic leukemia 17 years after continuous remission

Masatoshi Sakurai; Shintaro Watanuki; Jun Kato; Risa Hashida; Yusuke Yamane; Daiki Karigane; Takayuki Mitsuhashi; Mitsuru Murata; Hironori Ueno; Tomonori Nakazato; Shinichiro Okamoto; Takehiko Mori

doi:10.2169/internalmedicine.0807-18

Very late relapse of acute promyelocytic leukemia 17 years after continuous remission

Masatoshi Sakurai, Shintaro Watanuki, Jun Kato, Risa Hashida, Yusuke Yamane, Daiki Karigane, Takayuki Mitsuhashi, Mitsuru Murata, Hironori Ueno, Tomonori Nakazato, Shinichiro Okamoto, Takehiko Mori

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy. Nonetheless, relapse occurs in a certain proportion of patients, mostly within three to four years after treatment. We herein report a patient treated with ATRA and chemotherapy achieving remission who relapsed approximately 17 years after the treatment. A literature review identified 5 additional reported cases of APL relapse after more than 10 years. None of them presented with generally established risk factors for relapse, such as a high leukocyte count. The potential for late relapse of APL occurring more than 10 years after treatment should be recognized.

Original language	English
Pages (from-to)	3299-3302
Number of pages	4
Journal	Internal Medicine
Volume	57
Issue number	22
DOIs	https://doi.org/10.2169/internalmedicine.0807-18
Publication status	Published - 2018

Keywords

Acute promyelocytic leukemia
All-trans retinoic acid
Late relapse

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.0807-18

Cite this

@article{57824488c6364b7caf79e84ffa2ff630,

title = "Very late relapse of acute promyelocytic leukemia 17 years after continuous remission",

abstract = "The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy. Nonetheless, relapse occurs in a certain proportion of patients, mostly within three to four years after treatment. We herein report a patient treated with ATRA and chemotherapy achieving remission who relapsed approximately 17 years after the treatment. A literature review identified 5 additional reported cases of APL relapse after more than 10 years. None of them presented with generally established risk factors for relapse, such as a high leukocyte count. The potential for late relapse of APL occurring more than 10 years after treatment should be recognized.",

keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, Late relapse",

author = "Masatoshi Sakurai and Shintaro Watanuki and Jun Kato and Risa Hashida and Yusuke Yamane and Daiki Karigane and Takayuki Mitsuhashi and Mitsuru Murata and Hironori Ueno and Tomonori Nakazato and Shinichiro Okamoto and Takehiko Mori",

note = "Publisher Copyright: {\textcopyright} 2018 The Japanese Society of Internal Medicine.",

year = "2018",

doi = "10.2169/internalmedicine.0807-18",

language = "English",

volume = "57",

pages = "3299--3302",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "22",

}

TY - JOUR

T1 - Very late relapse of acute promyelocytic leukemia 17 years after continuous remission

AU - Sakurai, Masatoshi

AU - Watanuki, Shintaro

AU - Kato, Jun

AU - Hashida, Risa

AU - Yamane, Yusuke

AU - Karigane, Daiki

AU - Mitsuhashi, Takayuki

AU - Murata, Mitsuru

AU - Ueno, Hironori

AU - Nakazato, Tomonori

AU - Okamoto, Shinichiro

AU - Mori, Takehiko

PY - 2018

Y1 - 2018

N2 - The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy. Nonetheless, relapse occurs in a certain proportion of patients, mostly within three to four years after treatment. We herein report a patient treated with ATRA and chemotherapy achieving remission who relapsed approximately 17 years after the treatment. A literature review identified 5 additional reported cases of APL relapse after more than 10 years. None of them presented with generally established risk factors for relapse, such as a high leukocyte count. The potential for late relapse of APL occurring more than 10 years after treatment should be recognized.

AB - The prognosis of acute promyelocytic leukemia (APL) has been improved by the combination of all-trans retinoic acid (ATRA) with chemotherapy. Nonetheless, relapse occurs in a certain proportion of patients, mostly within three to four years after treatment. We herein report a patient treated with ATRA and chemotherapy achieving remission who relapsed approximately 17 years after the treatment. A literature review identified 5 additional reported cases of APL relapse after more than 10 years. None of them presented with generally established risk factors for relapse, such as a high leukocyte count. The potential for late relapse of APL occurring more than 10 years after treatment should be recognized.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - Late relapse

UR - http://www.scopus.com/inward/record.url?scp=85056659553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056659553&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.0807-18

DO - 10.2169/internalmedicine.0807-18

M3 - Article

C2 - 29984744

AN - SCOPUS:85056659553

SN - 0918-2918

VL - 57

SP - 3299

EP - 3302

JO - Internal Medicine

JF - Internal Medicine

IS - 22

ER -

Very late relapse of acute promyelocytic leukemia 17 years after continuous remission

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this